These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 32715967

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
    Tkacz J, Gharaibeh M, DeYoung KH, Wilson K, Collier D, Oko-Osi H.
    J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Assessing the Association of Formulary Copayment Changes with Real-World Treatment Patterns in Patients with Rheumatoid Arthritis on Etanercept.
    Bonafede M, Oko-Osi H, Gharaibeh M, Manjelievskaia J, Lopez-Gonzalez L, Collier DH, Stolshek BS.
    J Manag Care Spec Pharm; 2020 Feb; 26(2):211-220. PubMed ID: 31823689
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
    Curtis JR, Chastek B, Becker L, Quach C, Harrison DJ, Yun H, Joseph GJ, Collier DH.
    J Manag Care Spec Pharm; 2015 Apr; 21(4):318-29. PubMed ID: 25803765
    [Abstract] [Full Text] [Related]

  • 9. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
    Claxton L, Jenks M, Taylor M, Wallenstein G, Mendelsohn AM, Bourret JA, Singh A, Moynagh D, Gerber RA.
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1088-102. PubMed ID: 27579831
    [Abstract] [Full Text] [Related]

  • 10. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ, Princic N, Park J, Malatestinic WN, Zhu B, Atiya B, Kern SA, Stenger KB, Sprabery AT, Ogdie A.
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [Abstract] [Full Text] [Related]

  • 11. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
    Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.
    J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
    [Abstract] [Full Text] [Related]

  • 12. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M, Johnson BH, Princic N, Shah N, Harrison DJ.
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [Abstract] [Full Text] [Related]

  • 13. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
    Popp RA, Rascati K, Davis M, Patel U.
    Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
    [Abstract] [Full Text] [Related]

  • 14. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W.
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [Abstract] [Full Text] [Related]

  • 15. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A, Wailoo A.
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [Abstract] [Full Text] [Related]

  • 16. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N, Lee YC, Shah N, Harrison DJ.
    Clin Ther; 2014 Aug 01; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [Abstract] [Full Text] [Related]

  • 17. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.
    J Manag Care Pharm; 2013 Oct 01; 19(8):621-30. PubMed ID: 24074008
    [Abstract] [Full Text] [Related]

  • 18. Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study.
    Gu T, Shah N, Deshpande G, Tang DH, Eisenberg DF, Harrison DJ.
    J Health Econ Outcomes Res; 2016 Oct 01; 3(2):122-131. PubMed ID: 37663319
    [Abstract] [Full Text] [Related]

  • 19. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.
    J Manag Care Spec Pharm; 2014 Jul 01; 20(7):657-67. PubMed ID: 24967519
    [Abstract] [Full Text] [Related]

  • 20. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
    Chastek B, Becker LK, Chen CI, Mahajan P, Curtis JR.
    J Med Econ; 2017 May 01; 20(5):464-473. PubMed ID: 28010149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.